Search

REVOLUTION Medicines Inc

Открыт

СекторЗдравоохранение

210.64 -0.4

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

208.24

Макс.

215.55

Ключевые показатели

By Trading Economics

Доход

-644M

-1.1B

Прибыль на акцию

-2.34

Сотрудники

883

EBITDA

-184M

-621M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+5.35% upside

Дивиденды

By Acuity

Следующий отчет о доходах

4 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

6.7B

45B

Предыдущая цена открытия

211.04

Предыдущая цена закрытия

210.64

Новостные настроения

By Acuity

83%

17%

320 / 340 Рейтинг в Healthcare

REVOLUTION Medicines Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 авг. 2026 г., 20:06 UTC

Revolution Medicines Inc shares are higher today, recovering from an earlier low. The stock has gained since Friday's close amid rising oil prices.

21 авг. 2026 г., 19:46 UTC

News

Revolution Medicines shares are lower today as Bernstein raised its price target to $179, continuing a trend of three consecutive daily declines.

20 авг. 2026 г., 23:26 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

19 авг. 2026 г., 19:46 UTC

News

Revolution Medicines Inc shares are lower Wednesday, pulling back after reaching a session high. The stock has declined since Tuesday's close.

17 авг. 2026 г., 19:51 UTC

Social Media

Revolution Medicines shares are higher since Friday's close as Baker Bros boosts its stake to 11.4 million shares, valued at $2 billion.

13 авг. 2026 г., 19:36 UTC

Revolution Medicines Inc shares are lower, reaching a session low earlier. This decline follows a cumulative drop since Wednesday's close.

12 авг. 2026 г., 23:16 UTC

Revolution Medicines shares declined in after-market trading, despite earlier gains. The Consumer Price Index report showed a modest rise in consumer prices today.

11 авг. 2026 г., 19:36 UTC

News

Revolution Medicines Inc is trading lower as broader geopolitical tensions and upcoming U.S. inflation reports weigh on market sentiment.

10 авг. 2026 г., 23:51 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, maintaining a position above the 20-day moving average and near the one-month range's upper end.

7 авг. 2026 г., 19:11 UTC

News

Revolution Medicines Inc shares are higher as the company plans a Phase 3 study and Wedbush raises its price target to $201 from $192.

6 авг. 2026 г., 19:36 UTC

Social Media
News

Revolution Medicines Inc is trading higher as RBC Capital and Evercore ISI raise price targets, reflecting growing confidence in the company's clinical pipeline.

5 авг. 2026 г., 23:02 UTC

Social Media
News

Revolution Medicines shares lower in after-market trading following a second-quarter loss of $644.4 million and an EPS of -$3.06, missing estimates.

4 авг. 2026 г., 23:06 UTC

Revolution Medicines shares are lower in after-market trading, settling near Tuesday's close. The stock remains above its 20-day moving average.

3 авг. 2026 г., 23:26 UTC

Revolution Medicines Inc shares are trading higher in after-market hours. Broader market sentiment is positive, influenced by declining oil prices and reduced inflation concerns.

31 июл. 2026 г., 20:06 UTC

Revolution Medicines Inc. shares are lower amid broader market volatility and rising U.S. Treasury yields, which have heightened inflation concerns and interest rate expectations.

30 июл. 2026 г., 22:41 UTC

Revolution Medicines Inc. shares are lower in after-market trading, declining since Thursday's close amid fluctuations in bond yields and Fed policy uncertainty.

29 июл. 2026 г., 17:02 UTC

Revolution Medicines Inc shares are lower, continuing a four-session decline with unusually high trading volume. The stock remains below its 20-day moving average.

28 июл. 2026 г., 19:02 UTC

Revolution Medicines Inc shares are lower today, continuing a decline since Monday amid negative broader market sentiment following significant drops in Asian markets.

27 июл. 2026 г., 20:06 UTC

Revolution Medicines Inc shares are lower amid broader market dynamics, including a decline in oil prices and falling Treasury yields ahead of the Federal Reserve meeting.

24 июл. 2026 г., 18:26 UTC

Social Media
News

Revolution Medicines shares are lower amid broader market sentiment, despite RJ's increased price target of $230 and positive FDA news on daraxonrasib.

22 июл. 2026 г., 18:26 UTC

Revolution Medicines Inc shares are higher today amid broader geopolitical tensions affecting market sentiment, despite no specific company news driving the movement.

21 июл. 2026 г., 17:16 UTC

Revolution Medicines Inc shares are higher today, reflecting gains since Monday amid supportive market conditions and positive sentiment from Asian markets and easing oil prices.

20 июл. 2026 г., 17:31 UTC

Social Media
News

Revolution Medicines Inc. shares are lower today despite upcoming catalysts and a projected revenue estimate of $13-15 billion by 2035. Trading volume is unusually high.

Сравнение c конкурентами

Изменение цены

REVOLUTION Medicines Inc Прогноз

Целевая цена

By TipRanks

5.35% рост

Прогноз на 12 месяцев

Средняя 222.89 USD  5.35%

Максимум 291 USD

Минимум 179 USD

Основано на мнении 19 аналитиков Wall Street, спрогнозировавших целевые цены для REVOLUTION Medicines Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

19 ratings

18

Покупка

1

Удержание

0

Продажа

Настроения

By Acuity

320 / 340Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat